

1 **Suppression of influenza virus infection by rhinovirus interference at the**
2 **population, individual and cellular levels**

3

4 Kin P Tao, PhD^{1,2,3,4,†}, Marc Chong, PhD^{5,†}, Jason CS Pun, BSc^{1,2,3,4}, Joseph GS Tsun,
5 PhD^{1,2,3,4}, Samuel MW Chow, FRCS(Ed)⁶, Calvin SH Ng, MD⁷, Maggie HT Wang,
6 PhD⁵, Zigui Chan, PhD⁸, Paul KS Chan, MD⁸, Albert M Li, MD^{1,2,3,4}, Renee WY
7 Chan, PhD^{1,2,3,4,*}

8

9 ¹ Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong
10 Kong.

11 ² CUHK-UMCU Joint Research Laboratory of Respiratory Virus & Immunobiology,
12 Faculty of Medicine, The Chinese University of Hong Kong.

13 ³ Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong.

14 ⁴ Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health
15 Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
16 SAR.

17 ⁵ Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The
18 Chinese University of Hong Kong.

19 ⁶ Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese
20 University of Hong Kong.

21 ⁷ Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University
22 of Hong Kong.

23 ⁸ Department of Microbiology, Faculty of Medicine, The Chinese University of Hong
24 Kong.

25

26 [†]These authors contributed equally to this work.

27 ^{*}Corresponding Author

28

29 **Corresponding Author:**

30 Renee WY Chan, Assistant Professor

31 **Address:** Department of Paediatrics, 6/F, Lui Chee Woo Clinical Sciences Building,
32 Prince of Wales Hospital, New Territories, Hong Kong.

33 **Email:** reneewy@cuhk.edu.hk

34 **Abstract**

35

36 **Background:** Investigations of the natural viral interference effect between rhinovirus
37 (RV) and influenza virus (IV) were conducted in temperate regions. We conducted an
38 epidemiological study in Hong Kong, a major epicentre of influenza virus in the sub-
39 tropical region. RV is the most prevalent respiratory virus year-round and causes
40 asymptomatic to mild symptoms while IV infection exerts a great burden of public
41 health. We aimed to examine the correlation of RV prevalence against IV activity.

42 **Methods:** Nasopharyngeal aspirates (NPA) collected from patients hospitalized in the
43 regional hospitals from 2015 to 2019 were examined for the presence of respiratory
44 viruses. The correlation of the monthly prevalence between all pairs of virus infection,
45 the co-infection rate and the temporal interference of RV and IV were tested. The
46 viral interference was validated *in vitro* by conducting sequential RV and IV infection
47 in the well-differentiated primary human airway epithelial cells.

48 **Findings:** A total of 112,926 NPA were evaluated, and the Enterovirus/RV was the
49 most prevalent respiratory virus detected. The negative correlation between EV/RV
50 and IVs prevalence was independent of age and meteorological factors. Co-infection
51 of EV/RV and IV was significantly less when compared with other virus pairs. Prior
52 exposure to RV inhibited the replication of influenza A, B and oseltamivir-resistance
53 stain *in vitro* and the inhibition is replication dependent.

54 **Interpretation:** Epidemiological surveillance and the sequential infection *in vitro*
55 suggested viral interference between EV/RV and IV operated at the population,
56 individual and cellular levels.

57 **Funding:** This study was supported by the General Research Fund (Ref: 24107017
58 and 14103119 to RWYC), Health and Medical Research Fund (Ref: COVID190112

59 to RWYC) and the Chinese University Direct Grant for Research (Ref: 2019.073 to
60 RWYC).

61 **Introduction**

62 Influenza virus (IV) confers substantial morbidity and mortality worldwide every year.

63 The existence of natural reservoirs of IV makes it impossible to be eradicated in
64 humans.

65 Influenza vaccine is the classic preventive measure to attenuate disease severity.

66 However, the viral antigenic drift may limit the duration of vaccine effectiveness,¹

67 while the antigenic shift may result in the emergence of new strains.² Antivirals is

68 another prophylactic and therapeutic option with a limited effective time frame.³

69 Moreover, antiviral resistant IV strains have been reported sporadically, with an

70 increasing number of oseltamivir-resistant influenza A (R-IAV) is being found.⁴

71 Whether or not there is natural viral interference in counteracting the influence of IV

72 in the human population or individual levels is an interesting question to address.

73 Identifying novel interfering factors that confer temporal immunity against pan-

74 influenza and other virulent viral infections would provide alternative options for

75 disease prevention and treatment.

76

77 Rhinovirus (RV), on the other hand, is the most frequent respiratory pathogen being

78 detected throughout the year.⁵ However, it catches less attention in the public health

79 aspect as it generally causes mild and self-limiting symptoms, and sometimes it is

80 asymptomatic in healthy individuals.⁶ Nevertheless, infants could have up to six to

81 eight RV infections per year, while adults could have around two to four episodes

82 annually.⁷ Having RV infections repeatedly seems to be unavoidable as it comprises

83 more than 160 distinct genotypes. Among genotypes, they do not confer substantial

84 immunity against each other.⁸ Intriguingly, though the prevalence of RV is high, the

85 epidemiology study on RV is uncommon due to its high genotypic diversity. The

86 enterovirus/rhinovirus (EV/RV) test was not included as a standard test in clinical
87 labs until recent years. In Hong Kong, it has become available in public hospitals
88 since September 2015.

89

90 With the advancement for the co-detection of viruses through multiplex PCR,
91 multiple population-wide surveillance programs suggested that seasonality of
92 respiratory viral infection is not only contributed by meteorological factors but also
93 the biological interactions among different viruses. The concept of viral interference,
94 a phenomenon in which a primary virus infection could transiently prevent or inhibit
95 the secondary superinfecting virus,⁹ may also play an important role in influencing the
96 pattern of virus outbreaks. Multiple epidemiological analyses, including studies
97 performed in the United Kingdom and the United States, identified a negative
98 interaction between the prevalence of IVs and RVs,^{10,11} and viral interactions operate
99 at multiple levels.¹² In the epidemiological part of this study, we investigated
100 correlation of virus prevalence and the temporal interference between RV and IV at
101 the population level and the chance of co-infection at individual level. We validated
102 this concept further by conducting sequential infection study in the differentiated
103 primary human nasopharyngeal epithelial cells (HNEC) and human bronchial
104 epithelial cells (HBEC) to elucidate the inhibitory effect *in vitro*.

105

106 **Methods**

107 **Study population and dataset.** Nasopharyngeal aspirates (NPA) were collected from
108 patients admitted to the six hospitals under the Hong Kong New Territories East
109 Cluster and were screened routinely for respiratory viruses from September 2015 to
110 December 2019. Multiplex real-time PCR were performed by Public Health

111 Laboratory Centre, Centre for Health Protection, Department of Health, Hong Kong.
112 The respiratory virus panel, including influenza A virus (IAV, with subtyping of H1
113 and H3), influenza B virus (IBV), influenza C (ICV), parainfluenza viruses 1-4 (PIVs),
114 enterovirus/rhinovirus (EV/RV), respiratory syncytial viruses (RSV) and adenovirus
115 (ADV). The test-negative samples were retained as part of the essential denominator
116 to reflect the prevalence in the community to address the fluctuation in sample size
117 over the study period. This virological data covered nine episodes of IV peaks of four
118 consecutive years. Samples with missing or uncertain entries were excluded (<1%).
119 This study was approved by the Joint Chinese University of Hong Kong – New
120 Territories East Cluster Clinical Research Ethics Committee (CREC: 2015.097 and
121 2019.120).

122

123 **Meteorological data.** We obtained the meteorological data including ambient
124 temperature (°C) and mean relative humidity (%) measured at the central monitoring
125 station run by the Hong Kong Observatory. The weekly averages of meteorological
126 record were matched with the prevalence over the study period. As absolute humidity
127 was showed to be associated with the respiratory infections,¹³⁻¹⁵ we employed actual
128 vapour pressure (hPa) as a proxy of this humidity measure. The derivation of actual
129 vapour pressure was based on Tetten's formula,¹⁶

130
$$e = \frac{RH}{100} \times 6.105 \times \exp\left(\frac{17.27 \times TEMP}{237.7 + TEMP}\right)$$

131 where e, TEMP, and RH denote actual vapour pressure, ambient temperature, and
132 relative humidity respectively.

133

134 **Cell lines.** H1-HeLa (CRL-1958) and Madin-Darby canine kidney cells (MDCK,
135 CCL-34) were purchased from American Type Culture Collection. Cells were

136 cultured in minimal essential media with non-essential amino acids, 2mM L-
137 glutamine supplemented with 1% penicillin and streptomycin, and 10% fetal bovine
138 serum. Both cell lines were maintained at 37°C and used for RV and IV virus
139 propagation and titration.

140

141 **Virus preparation.** RV-1B (VR-1645) and RV-A16 (VR-283PQ) were purchased
142 from ATCC and were propagated in H1-HeLa. RV-A16 is a major group RV utilizing
143 ICAM1 as the cellular receptor, and RV-1B belongs to the minor group utilizing
144 LDLR as the cellular receptor, were chosen for this proof-of-concept *in vitro* infection.
145 Seasonal IAV (H1N1 human isolate A/Oklahoma/447/2008), IBV (B/Hong
146 Kong/CUHK/12v033261/2012) and an oseltamivir-resistant H1N1 swine IAV
147 (A/Hong Kong/CUHK/09v071923/2009) were isolated from the NPA of patients and
148 were propagated using MDCK cells. Virus progeny was harvested when the
149 cytopathic effect (CPE) was observed. Virus titers were determined by a viral titration
150 assay.

151

152 **Virus titration.** H1-HeLa and MDCK cells were seeded on 96-well tissue culture
153 plates one day before the viral titration assay. Cells were washed once with PBS.
154 Virus samples or culture supernatants were titrated in serial half- \log_{10} dilutions with
155 the corresponding culture medium before adding the diluted virus to the cell plates in
156 quadruplicate. The highest viral dilution leading to CPE was recorded and the 50%
157 tissue culture infectious dose (TCID₅₀) was calculated using the Karber method. The
158 infectivity of RV and IV was monitored by the infectious viral load in the supernatant,
159 as quantitated by viral titration in H1-HeLa or MDCK cells, respectively.

160

161 **Airway epithelial cell isolation and differentiation.** Human nasopharyngeal
162 epithelial cells (HNEC) and bronchial epithelial cells (HBEC) were isolated from
163 nasopharyngeal flocculated swab and bronchial tissue as described ¹⁷. Briefly, cells were
164 seeded in a 6 well plate coated with human collagen IV and cultured with BEpiCM
165 (Sciencecell): Advanced DMEM (Life Technologies) 1:1 supplemented with HEPES,
166 PS, primocin, glutamax, B27, hydrocortisone, triiodothyronine (T3), epinephrine, N-
167 acetyl-cysteine, nicotinamide, TGF β inhibitor, BMPi, Rocki, FGF10, FGF7, IGF-1,
168 BSA and R-spondin 1 conditioned medium. Upon confluence, cells were dissociated
169 by TrypLE and seeded onto PureCol coated transwell with a cell density of
170 2×10^5 cell/well in a 24-well format, and cultured in an air-liquid interface (ALI) using
171 differentiated PneumoCult ALI medium (StemCell) for at least 28 days before
172 infection experiments. Demographics of the donors were provided in **Supplementary**
173 **Table 1.**

174

175 *Experimental design of the sequential RV-A16 and IV virus infection in vitro.*
176 Primary HBECs and HNECs were washed with 125ul of PBS five times before
177 infection. Cells were exposed to infection regime 1) RV, 2) IV or 3) a prior RV
178 infection then a IV infection at 48 hpi of the initial RV inoculation at a multiplicity of
179 infection (MOI) of 0.01 (**Figure 6A**). In the infection step, 100ul of RV or sham
180 inoculum were added and allowed for virus attachment for 2 hours at 37°C. The
181 inoculum was discarded, and the cells were washed with PBS twice and the
182 basolateral compartment was replenished with 600ul of the medium. At 48 hours post
183 infection (hpi) of RV, cells were washed with PBS twice before secondary infection
184 of IAVs. The supernatant from the apical compartment of the transwell inserts were

185 collected at 2, 24 and 48 hpi for viral titers determination and gene expression
186 analysis.

187

188 **RNA extraction and gene expression analysis.** QIAGEN Viral RNA extraction kit
189 and RNaeasy Kit were used according to the manufacturer's instructions for RNA
190 extraction followed by qPCR. Viral RNA and total RNA were reverse transcribed into
191 cDNA with a PrimerScript RT reagent Kit (Takara). mRNA expression was measured
192 by real-time PCR amplification with SYBR Premix Ex Taq II (Tli RNase H Plus)
193 (Takara) and an ABI Quant Studio 12K real-time PCR system (Applied Biosystems).
194 Absolute quantification of IAV matrix 1 gene was done with standard plasmids and
195 normalized by housekeeping gene GAPDH. Primers used in this study were:

196 GAPDH-F: GTCTCCTCTGACTTCAACAGCG;

197 GAPDH-R: ACCACCCTGTTGCTGTAGCCAA;

198 IAV-matrix gene-F: GGCATTTTGGACAAAKCGTCTA;

199 IAV-matrix gene -R: CTTCTAACCGAGGTCGAAACG

200

201 **Statistical analysis**

202 The association of the monthly prevalence between all pairs of virus infections was
203 tested using Spearman's rank correlation coefficients. To assess whether IV
204 prevalence was statistically associated with the evolution of the future values EV/RV
205 prevalence, the Granger causality test was conducted and the significant lagged week
206 of IV prevalence was determined.¹⁸ To examine the association between EV/RV and
207 IV prevalence independent of meteorological effects at different lagged times, a
208 quasi-Poisson generalized additive model (GAM) was used to control the total
209 number of weekly collected samples (i.e. model offset), long-term trend, and seasonal

210 trend. The technical detail has been noted in the Supplementary File. The effect of
211 EV/RV on IV prevalence was quantified using adjusted relative risk (ARR) along
212 with its corresponding 95% confidence interval (CI). The reference value was set as
213 its median value.

214

215 The likelihood of viral co-infection was computed by Fisher's exact test and logistic
216 regression after adjustment to age and gender. Age group stratification with toddlers
217 (age <2), preschool (age 2-5), school-age (age 6-17), adult (age 18-64) and elderly
218 (age >65) were segregated for regression analysis. Differences in influenza titers and
219 viral gene expression was compared at respective time points with or without prior
220 EV exposure using two-way ANOVA followed by *Bonferroni* post-test for multiple
221 comparisons. One sample t-test was used to compare the changes (\log_{10} transformed)
222 in IV titer with prior RV infection, with null hypothesis assuming no difference with
223 sham treated control cells isolated from the same individuals. All statistical tests were
224 performed using Graphpad version 9.2.0 and IBM SPSS Statistics. Differences were
225 considered statistically significant at $p < 0.05$.

226

227 **Results**

228 **Opposing seasonality of EV/RV and IVs.** A total of 112,926 NPA were included in
229 this study. EV/RV was the most prevalent viral infection (**Figure 1B**), and it
230 contributed a monthly positive rate of at least 8% throughout the study period (**Figure**
231 **2**, red line). IVs were the second most dominant viral group being detected (**Figure 2**,
232 navy line). Combining IAV, IBV and ICV, reached up to 35% positive rate during flu
233 season but remained low for the rest of the year. A strong seasonal pattern was
234 observed in both EV/RV and IVs, with robust biannual peaks of EV/RV occurred

235 during spring and autumn, and one to two peaks of IV occurred in summers and
236 winters of Hong Kong, yet the onset, magnitude, duration and dominating subtypes of
237 the peaks varied extensively (**Figure 2**). A staggered pattern between EV/RV and IVs
238 has been observed in which the intensity of flu peaks was often higher after a low
239 EV/RV season. During the spring of 2017, the shortest period of EV/RV peak was
240 followed by an early outburst of IAV of the H3N2 subtype.

241

242 **Negative correlation between the prevalence of EV/RV with IVs.** Interactions
243 between viruses may be confounded by other factors such as the age of the subjects
244 and meteorological factors during sampling. In the current study, we analyzed the
245 virological data by age stratification (**Figure 1C**). EV/RV was the most prevalent in
246 those aged under 2 years old, while the median age of IAV and IBV positive cases
247 was significantly higher (11.19 and 7.84 years old, respectively) than that of EV/RV
248 (4.01 years old). Due to the variation of the influenza subtypes each year, IAV-H1,
249 IAV-H3, IBV and ICV were combined as IVs for regression analysis. Logistic
250 regression analysis revealed a significant negative correlation between the monthly
251 prevalence of EV/RV against IVs (-0.421 , $p < 0.01$, **Figure 3C, navy**) but not with
252 other virus pairs, such as PIVs, RSV and ADV. Spearman's bivariate analysis showed
253 a similar result in which a significant negative correlation was identified between
254 EV/RV against total IVs or IAV (**Table 1**). Significant negative correlations between
255 the monthly IVs prevalence and PIV2 and PIV4 were though their intensities were not
256 as strong as that between IVs and EV/RV.

257

258 **Time series causality.** IV prevalence was significantly associated with the evolution
259 of EV/RV ($p < 0.001$) and the effect of IV was highly significant at lag zero ($p < 0.001$),

260 indicating a non-lagged interference between IV and EV/RV as assessed by the
261 Granger causality test. The disease-disease association at lag zero was further
262 examined via GAM analysis and a significant negative association between IV and
263 EV/RV was showed (**Figure 4**). The ARR of EV/RV was 0.652 (95% CI: 0.571 to
264 0.745) when the prevalence of IV increased to 31.3% (i.e. 95th percentile of IV),
265 whereas the ARR of EV/RV was 1.159 (95% CI: 1.079 to 1.244) when the prevalence
266 of IV decreased to 1.5% (i.e. 5th percentile of IV), with a median reference value
267 (9.3%).

268

269 Moreover, the negative relationship between EV/RV and IV was independent to
270 meteorological variations from both ambient temperature & relative humidity and
271 absolute humidity. After controlling the effect of temperature and relative humidity,
272 the ARR of EV/RV was 0.654 (95% CI: 0.572 to 0.748) when the prevalence of IV
273 was at its 95th percentile. An increase of lagged time of IV demonstrated a sinusoidal
274 change in the ARR of EV/RV, highlighting a counteracting oscillation between the
275 two infections (**Supplementary Figure 1**).

276

277 **Reduced likelihood of EV/RV and IVs co-infection.** Co-infection of respiratory
278 viruses is common in hospitalized patients. Overall, 9.1% (n=2,582) of the NPA
279 samples were co-detected with two or more respiratory viruses, and 59.8% of these
280 co-infection cases were contributed by EV/RV (n=1,545) (**Figure 5A**). Co-infections
281 were more common in children, in which more than 80% of cases were found in
282 paediatric patients with age under 18 (**Figure 5B**). Interestingly, the odds to have both
283 EV/RV-IVs detected in the same specimen was exceptionally low (OR=0.15) when
284 compared with 0.75 for EV/RV-PIVs, 0.54 for EV/RV-RSV and 0.94 for EV/RV-

285 ADV co-detection using Fisher's Exact Test (**Figure 5C**). A further reduction in odds
286 was observed between EV/RV and IVs after the adjustment of the confounding effect
287 due to age and gender by binary logistic regression (**Figure 5D**).

288

289 **Sequential infection of RV and IV in HBEC and HNEC.** To address if viral
290 interference between IV and RV occurs at the cellular level, a sequential infection
291 was performed on well-differentiated human airway epithelial cells (**Figure 6A**). RV-
292 A16 and RV-1B and seasonal IAV, IBV and R-IAV showed productive replication
293 and achieved a 2- \log_{10} increase at 48 hpi. HBEC were susceptible to RV-A16 and
294 RV-1B infection and replication without cytopathic changes, while IV infection led to
295 obvious CPE at 48hpi (**Supplementary Figure 2**).

296

297 **Suppression of IAV infection and replication with prior exposure to RV-A16 and**
298 **RV-1B in HBEC and HNEC.** Prior exposure to RV-A16, the IV replication was
299 inhibited. The viral load was significantly inhibited with a mean reduction of 1.44
300 \log_{10} and 1.22 \log_{10} in HBECs and 2.95 \log_{10} and 2.58 \log_{10} in HNECs at 24 h and 48
301 h post influenza virus infection, respectively, compared with those exposed to sham
302 treatment. (**Figure 6B**). A significant reduction in the normalized IAV matrix gene
303 copies was also observed in both cell types (**Supplementary Figure 2I**).

304

305 **Active RV replication is essential to exert viral interference.** Heterogenicity in
306 individual's susceptibility to RV was observed. HNECs derived from 4 out of 5
307 donors, and HBECs derived from 6 out of 9 donors supported productive replication
308 of RV (**Supplementary Table 1 and Supplementary Figure 3**). Importantly, we
309 found that the interference effect depended on the active replication of RV. The

310 inhibition effect to IAV infection was abolished in non RV-replicating cells. Using
311 ultraviolet-inactivated RV-A16 as the inoculum, we confirmed this observation again
312 and found that the UV-inactivated virus did not suppress the subsequent IVA and IVB
313 replication.

314

315 **Suppression of IBV and oseltamivir-resistant IAV with prior exposure to RV-**
316 **A16 and RV-1B in HBEC.** The suppression by the prior exposure of RV-A16 was
317 not limit to IAV. A significant reduction of IBV (1.91 log₁₀, and 2.25 log₁₀ at 24hpi
318 and 48hpi, $p < 0.05$) and oseltamivir-resistant IAV strain (3.85 log₁₀ and 2.64 log₁₀ at
319 24 and 48hpi respectively, $p < 0.01$, **Figure 6C**) was observed in RV-A16 infected
320 cells compared with sham-exposed HBECs. Moreover, RV exposure protected HBEC
321 from IAV induced cell death. Extensive CPE was starting from 48hpi, while no CPE
322 was observed for at least 7 days if the cells were infected with RV-A16 before IVA
323 infection (**Supplementary Figure 2C to 2H**). To rule out if the observation is a
324 specific effect of RV-A16, the same experiment setting was carried out using RV-1B
325 in HBECs. RV-1B suppressed the IAV replication by 2.59 log₁₀ at 48hpi but not at an
326 earlier time point (**Figure 6D**). Taken together, our result supports that RV infection
327 attenuates the subsequent influenza replication in primary human respiratory
328 epithelial cells.

329

330 **Discussion**

331 The influenza virus exerts a great burden on the health system each year in terms of
332 frequent medical visits, hospitalization and flu-related death. We demonstrated the
333 viral interference between RV and IVs using epidemiological data and biological
334 experiments, suggesting a broad protective role of EV/RV in inhibiting subsequent

335 IVs. We evaluated this interaction using the epidemiological data collected from
336 hospitalized patients from September 2015, when the EV/RV test was first introduced
337 as a routine test in the clinical settings, to December 2019, the last normal month
338 before the SARS-CoV-2 pandemic began. In this study, a total of 112,926 NPA
339 obtained from all ages were examined. The negative association between EV/RV and
340 IVs prevalence was independent of subject age and meteorological factors. Consistent
341 with studies performed in different climatic parameters,^{10,11} an interference effect in
342 population-level is suggested. We also demonstrated the competitive effect between
343 the two could also operate at the individual level as the likelihood of getting co-
344 detection between EV/RV and IVs was exceptionally low compared with other virus
345 pairs. During these nine flu seasons in Hong Kong, it is intriguing to see that EV/RV
346 prevalence oscillated in a counteracting manner. For example year 2015, 2018 and
347 2019 represented the lowered EV/RV positive rate of winters (November to February
348 of the next year) within the study window were followed by some of the most intense
349 winter flu outbreaks. The opposite is true for the summer of 2018. While experiencing
350 the highest summer EV/RV prevalence within the period, the intensity of flu within
351 the same season was almost abolished. The magnitude of concurrent RV peak may
352 forecast the intensity of IVs in the same season which is beneficial for public health
353 management before flu outbreaks.

354 To convey the observation of viral interference from *in vitro* settings to the population
355 level, a transmission study using animal models will be a choice. It has been shown
356 that prior exposure to RV-1B can reduce the severity of mouse-adapted IAV PR8 in a
357 dose-dependent manner.¹⁹ In the same study, mice with a double-stranded RNA
358 (dsRNA) mimic before IAV infection significantly reduce viral load. Aligned with
359 our findings in cells that did not support RV replication and UV-inactivated RV, it has

360 been shown that UV-inactivated RV cannot induce antiviral cytokine responses.²⁰ The
361 lack of inhibitory effect to subsequent IAV infection suggested that active virus
362 replication within the host is required. Viral interference may be mediated by factors
363 such as IFNs, defective interfering particles, production of trans-acting proteases,
364 cellular factors, and nonspecific dsRNA.²¹ A recent finding from an *in vivo* mouse
365 model suggested that inhibition of IAV PR8 by RV depended on type I IFN signalling
366 pathway.²²

367

368 It has been shown that nonpharmaceutical interventions such as ethanol hand rub and
369 facemasks are not effective in controlling the transmission of non-enveloped EV/RVs
370 ^{23,24}. During the SARS-CoV pandemic, hospitalization and positive rate for detected
371 enveloped virus including IVs, PIVs and RSV were drastically reduced but that of
372 EV/RV was less affected throughout 2020 ²⁵. Excluding the period of SARS-CoV-2
373 pandemic is necessary to address the interference effect in the community as the
374 implementation of social distancing measures and enhanced personal hygiene has a
375 great effect in suppressing the transmissibility of respiratory viruses. Using a similar
376 experimental design, our preliminary *in vitro* infection model suggested that prior
377 RV-A16 infection could suppress SARS-CoV-2 replication using HBEC
378 (**Supplementary Figure 4**). A recent finding suggested that the protective effect
379 conferred by prior EV exposure in respiratory cells is again due to the induction on
380 IFN-stimulated genes shared high consistency with our findings ²⁶.

381

382 *In vitro* infection using ALI differentiated cells and mathematical simulations also
383 agree that RV has an interference effect against SARS-CoV-2 at multiple levels. ²⁷
384 These results all point to the fact that EV/RV infection, which usually causes mild or

385 asymptotic infection in healthy individuals, may provide at least transient protective
386 effect against more virulent viral infections such as influenza and SARS-CoV-2.
387 Immunomodulatory effect due to mild EV/RV effect may serve as a novel antiviral
388 defense against emerging outbreaks when therapeutics are not available.
389 Understanding the molecular mechanism on how EV/RV triggering innate immunity
390 may shed light on novel prophylactics design against board range of viral infections.

391

392 **Limitations:** The viral interference window induced by RVs to IVs *in vitro* was up to
393 48 hours and the maximal duration is yet to define. We demonstrated that the
394 inhibitory effect was significant for at least 48 hours post influenza virus infection.
395 However, the exact durability of the inhibition exerted by RV was not thoroughly
396 assessed in this setting because of extensive cell death in the sham-treated cells
397 (**Supplementary Figure 3H**). Moreover, we did not investigate if the suppression of
398 IAV by RV relate to impairment of influenza virus receptor. Nevertheless, a previous
399 study showed that RV-A16 infection on HBEC did not alter the transcription of α 2-6-
400 linked and α 2-3-linked sialyl-transferases, which are responsible producing the
401 relevant sialic acid receptor, thus the restriction on IVA is independent of the change
402 in receptor availability.²⁸ Lastly, the action of competition between RV and IV by
403 adding the virus together at the same time point or prior infection of IV to subsequent
404 RV infection was not evaluated. The latter could not be evaluated in our human
405 primary respiratory epithelial cell culture, as the IV would cause a significant CPE
406 even at a low MOI.

407

408 **Conclusion**

409 The cumulative evidence suggests the occurrence of viral interference at the
410 population, individual and cellular level. The understudied role of RV in providing
411 the baseline immunity to influenza virus replication warrants further attention.

412 **Acknowledgements**

413 We would like to acknowledge Professor Gillian M Air of the University of
414 Oklahoma Health Sciences Center who provides IAV strain A/Oklahoma/447/2008
415 H1N1 for the study; Drs Steffi X Long and Louisa LY Chan for culturing the human
416 primary epithelial cells the study; Ms Waii WY Yu for her assistance in the molecular
417 biology experiments. Drs Michael CW Chan and Dr Kenrie PY Hui for the SARS-
418 CoV-2 infection.

419

420 **Authors contributions**

421 Conception, experimental design, drafting the manuscript and interpretation: KPT,
422 MKCC and RWYC; Data Analysis: KPT, MKCC, JSCP, MHW, RWYC; Collection
423 of bio-specimen: JGST, SMWC, CSHN, ZC, PKSC, AML; Execution of experiment
424 and acquisition of data: KPT and JCSP. All authors reviewed and approved the final
425 manuscript.

426 **Reference**

- 427 1. Cao L, Lou J, Zhao S, et al. In silico prediction of influenza vaccine
428 effectiveness by sequence analysis. *Vaccine* 2021; **39**(7): 1030-4.
- 429 2. Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. *N Engl*
430 *J Med* 2004; **350**(3): 218-20.
- 431 3. Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for
432 healthy adults: a systematic review and meta-analysis. *Lancet Infect Dis* 2009; **9**(9):
433 537-45.
- 434 4. Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and
435 changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United
436 Kingdom, winter 2010/11. *Euro Surveill* 2011; **16**(5).
- 437 5. Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner.
438 *Arch Fam Med* 2000; **9**(9): 913-20.
- 439 6. Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children
440 and Adults: Comparing Asymptomatic Controls and Patients With Community-
441 Acquired Pneumonia. *J Infect Dis* 2016; **213**(4): 584-91.
- 442 7. Chen WJ, Arnold JC, Fairchok MP, et al. Epidemiologic, clinical, and
443 virologic characteristics of human rhinovirus infection among otherwise healthy
444 children and adults: rhinovirus among adults and children. *J Clin Virol* 2015; **64**: 74-
445 82.
- 446 8. Glanville N, Johnston SL. Challenges in developing a cross-serotype
447 rhinovirus vaccine. *Curr Opin Virol* 2015; **11**: 83-8.
- 448 9. Henle W. Interference phenomena between animal viruses; a review. *J*
449 *Immunol* 1950; **64**(3): 203-36.
- 450 10. Nickbakhsh S, Mair C, Matthews L, et al. Virus-virus interactions impact the
451 population dynamics of influenza and the common cold. *Proc Natl Acad Sci U S A*
452 2019.
- 453 11. Wu A, Mihaylova VT, Landry ML, Foxman EF. Interference between
454 rhinovirus and influenza A virus: a clinical data analysis and experimental infection
455 study. *Lancet Microbe* 2020; **1**(6): e254-e62.
- 456 12. Opatowski L, Baguelin M, Eggo RM. Influenza interaction with cocirculating
457 pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key
458 role for mathematical modelling. *PLoS Pathog* 2018; **14**(2): e1006770.
- 459 13. Chong KC, Lee TC, Bialasiewicz S, et al. Association between meteorological
460 variations and activities of influenza A and B across different climate zones: a multi-
461 region modelling analysis across the globe. *J Infect* 2020; **80**(1): 84-98.
- 462 14. Chong KC, Liang J, Jia KM, et al. Latitudes mediate the association between
463 influenza activity and meteorological factors: A nationwide modelling analysis in 45
464 Japanese prefectures from 2000 to 2018. *Sci Total Environ* 2020; **703**: 134727.
- 465 15. Leung SY, Lau SYF, Kwok KL, Mohammad KN, Chan PKS, Chong KC.
466 Short-term association among meteorological variation, outdoor air pollution and
467 acute bronchiolitis in children in a subtropical setting. *Thorax* 2021; **76**(4): 360-9.
- 468 16. Tetens O. Über einige meteorologische Begriffe. *Z Geophys* 1930; **6**: 297-309.
- 469 17. Chan RW, Chan MC, Nicholls JM, Malik Peiris JS. Use of ex vivo and in
470 vitro cultures of the human respiratory tract to study the tropism and host responses of
471 highly pathogenic avian influenza A (H5N1) and other influenza viruses. *Virus Res*
472 2013; **178**(1): 133-45.
- 473 18. Granger C. Investigating Causal Relations by Econometric Models and Cross-
474 spectral Methods. *Econometrica* 1969; **37**(3): 424-38.

- 475 19. Gonzalez AJ, Ijezie EC, Balemba OB, Miura TA. Attenuation of Influenza A
476 Virus Disease Severity by Viral Coinfection in a Mouse Model. *J Virol* 2018; **92**(23).
477 20. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-
478 induced disease and exacerbation of allergic airway inflammation. *Nat Med* 2008;
479 **14**(2): 199-204.
480 21. Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT. Virological and
481 Immunological Outcomes of Coinfections. *Clin Microbiol Rev* 2018; **31**(4).
482 22. Van Leuven JT, Gonzalez AJ, Ijezie EC, et al. Rhinovirus Reduces the
483 Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and -
484 Independent Mechanisms. *mSphere* 2021; **6**(3): e0047921.
485 23. Savolainen-Kopra C, Korpela T, Simonen-Tikka ML, et al. Single treatment
486 with ethanol hand rub is ineffective against human rhinovirus--hand washing with
487 soap and water removes the virus efficiently. *J Med Virol* 2012; **84**(3): 543-7.
488 24. Chen AP, Chu IY, Yeh ML, et al. Differentiating impacts of non-
489 pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral
490 infections: Hospital-based retrospective observational study in Taiwan. *Influenza*
491 *Other Respir Viruses* 2021.
492 25. Centre for Health Protection HKSAR. Statistics on Laboratory Surveillance.
493 2021.
494 26. Cheemarla NR, Watkins TA, Mihaylova VT, et al. Magnitude and timing of
495 the antiviral response determine SARS-CoV-2 replication early in infection. *medRxiv*
496 2021.
497 27. Dee K, Goldfarb DM, Haney J, et al. Human rhinovirus infection blocks
498 SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-
499 19 epidemiology. *The Journal of Infectious Diseases* 2021.
500 28. Proud D, Hudy MH, Wiehler S, et al. Cigarette smoke modulates expression
501 of human rhinovirus-induced airway epithelial host defense genes. *PLoS One* 2012;
502 **7**(7): e40762.
503 29. Essaidi-Laziosi M, Geiser J, Huang S, Constant S, Kaiser L, Tapparel C.
504 Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections
505 of Airway Epithelia. *Sci Rep* 2020; **10**(1): 10246.
506

<i>p</i>	IAV	IBV	ICV	PIV1	PIV2	PIV3	PIV4	RSV	ADV	IVs
EVRV	-0.421**	0.096	-0.223	0.117	0.114	0.240	0.147	0.052	0.138	-0.477***
IAV		-0.217*	-0.025	0.126	-0.350**	-0.184	0.042	0.078	-0.120	-
IBV			0.081	-0.186	-0.289*	0.224	-0.232	-0.022	-0.100	-
ICV				-0.147	0.277*	0.138	0.025	-0.426**	-0.125	-
PIV1					0.038	0.275	0.415*	-0.172**	-0.051	0.047
PIV2						0.098	-0.053	-0.178	-0.090	-0.428**
PIV3							0.084	-0.396*	-0.011	-0.061
PIV4								-0.047	0.059	-0.109**
RSV									-0.032	-0.044
AdV										-0.199

Table 1. Correlation of viral prevalence. Bivariate Spearman’s cross-correlation coefficients between respiratory viruses using the monthly prevalence are shown. Asterisks indicate significance at $p < 0.05^*$, $p < 0.01^{**}$ and $p < 0.001^{***}$. IVs in the last column indicates the sum of IAV, IBV and ICV, the cross-correlation within the IVs and IAV, IBV and ICV are therefore excluded from the analysis. Red and blue values indicate a negative and positive correlation, respectively.

A. Demographics			
	Groups	No. of Patients	Percentage
Age Group	<2	17,025	15.08%
	2-5	19,183	16.99%
	6-17	11,570	10.25%
	18-64	18,041	15.98%
	>65	47,107	41.71%
Gender	Female	49,997	44.27%
	Male	62,929	55.73%
B. Virological Readout (n=112,926)			
		No. of Patients	Percentage
All negative		73,736	65.30%
Positively detected with		39,190	34.70%
Enterovirus/Rhinovirus		13,575	12.02%
Influenza A virus		9,831	8.70%
H1 subtype		3,757	3.34%
H3 subtype		6,081	5.38%
Influenza B virus		3,546	3.14%
Influenza C virus		381	0.34%
Parainfluenza 1		1,325	1.17%
Parainfluenza 2		766	0.68%
Parainfluenza 3		2,468	2.19%
Parainfluenza 4		1,363	1.21%
Respiratory Syncytial Virus		4,765	4.22%
Adenovirus		3,899	3.45%




Figure 1. (A) Demographics of the patients included in the inpatient study from September 2015 to December 2019. (B) Virological readouts were obtained from all 112,926 NPA samples for the detection of virus infection by multiplex PCR. Subtyping of H1 and H3 were performed after positive IAV detection. (C) A violin plot showing the age distribution of virus infections from test-positive 39,190 NPA samples presents individual data as grey dots. The blue line shows the median age, and the red lines show the interquartile range.




Figure 2. Temporal dynamics of respiratory virus prevalence in the inpatient cohort from September 2015 to December 2019. Monthly prevalence of individual virus infections (left y-axis) with the respective number of tested samples showed in grey bars (right y-axis) throughout the study period. EV/RV = enterovirus/rhinovirus; IVs = influenza viruses; PIVs = parainfluenza viruses; RSV = respiratory syncytial viruses; ADV =adenovirus.




Figure 3: Negative correlation between the prevalence of EV/RV and IVs. (A) Prevalence of individual virus infections of different age groups is represented by the colour lines (left y-axis). The grey bar represents the number of samples tested in each group (right y-axis). (B) Prevalence of influenza subtypes (gradients of blue) compared to EV/RV (red) across the five-year study period. Typical influenza season (December to March, July to August) in Hong Kong is shaded in grey. (C) Logistic regression between the prevalence of EV/RV with other viruses with 95% CI marked in dotted lines. Significant negative correlation (-1.596 ± 0.3110 , $p < 0.001^{***}$ with $R^2 = 0.3123$) was identified only between EV/RV and IVs.





Figure 4. Adjusted relative risks (ARRs) with 95% confidence interval on EV/RV against IV prevalence. The estimated ARR without controlling meteorological effects, with ambient temperature plus relative humidity controlled, and with actual vapor pressure adjusted are expressed as blue, red, and green colors respectively. Median IV prevalence was used as the reference value for comparison.

A

Viruses	Sample with >1 viruses detected	Sample detected with sole virus	Co-detection rate
EV/RV	1,545	13,575	11.38%
IAV	627	9,831	6.38%
IBV	206	3,546	5.81%
ICV	168	381	44.09%
PIV1	174	1,325	13.13%
PIV2	150	766	19.58%
PIV3	388	2,468	15.72%
PIV4	496	1,363	36.39%
RSV	663	4,765	13.91%
ADV	894	3,899	22.93%
Overall	2,582	39,190	2.29%

B



C

Virus pair	Expected	Observed	OR (95% CI)	
EV/RV – IVs	1644	310	0.15 (0.13 – 0.17)	***
EV/RV – PIVs	701	546	0.75 (0.68 – 0.82)	***
EV/RV – RSV	573	331	0.54 (0.48 – 0.60)	***
EV/RV – Adv	469	444	0.94 (0.85 – 1.04)	ns
IVs – PIVs	706	252	0.32 (0.28 – 0.36)	***
IVs – RSV	577	134	0.20 (0.17 – 0.24)	***
IVs – Adv	472	198	0.38 (0.33 – 0.44)	***
PIVs – RSV	246	136	0.52 (0.45 – 0.63)	***
PIVs – Adv	201	210	1.05 (0.91 – 1.21)	ns
RSV – Adv	165	104	0.61 (0.54 – 0.74)	***

D

Variables	Group	RV prevalence		IVs prevalence	
		Adjusted OR (95% CI)		Adjusted OR (95% CI)	
Gender	Female	1		1	
	Male	1.16 (1.12 – 1.21)	***	0.92 (0.88 – 0.95)	***
Age Group	< 2	1		1	
	2 - 5	1.32 (1.25 – 1.39)	***	2.16 (2.03 – 2.30)	***
	6 – 17	0.66 (0.62 – 0.70)	***	1.81 (1.69 – 1.94)	***
	18 – 64	0.20 (0.19 – 0.22)	***	0.65 (0.61 – 0.70)	***
	> 65	0.16 (0.15 – 0.17)	***	0.46 (0.43 – 0.49)	***
Co-detection	IVs	0.091 (0.081 – 0.10)	***	-	-
	RV	-	-	0.091 (0.081 – 0.10)	***
	PIVs	0.34 (0.31 – 0.38)	***	0.20 (0.17 – 0.23)	***
	RSV	0.22 (0.21 – 0.24)	***	0.12 (0.10 – 0.14)	***
	Adv	0.39 (0.35 – 0.43)	***	0.19 (0.88 – 0.95)	***

Figure 5. Co-infection statistics. (A) Rate of co-detecting more than one respiratory virus in different respiratory virus infection. The number of NPA samples detected with more than one pathogen detected was divided by the total number of the sample test-positive with the agent listed in each row. (B) Breakdown of co-infection cases according to age group. (C) The odd ratio of EV/RV and IVs co-infection with other respiratory pathogens using Fisher's exact test with null hypothesis assuming the likelihood of individual infection events were not interrelated (D) Logistic regression analysis of EV/RV and IV infection after adjustment to gender and age group with the same adjustments.




Figure 6. RVs suppress subsequent IVs infection in vitro. (A) Experimental plan of the model. Fully differentiated ALI cultures were first infected (or sham-treated) with RVs for 2 days, followed by secondary infection of IVs. Supernatant and cell lysates were collected at 2, 24 and 48 hours post infection (hpi) for determination of viral load and gene expression. (B) Suppression of IVA titers with prior RV-A16 infection in HBEC (n=9) and HNEC (n=5). Y-axis represents the difference in titer in RV exposed to the sham-treated cells. (C) Suppression of IVB and oseltamivir-resistance stain of IVA (R-IVA) in HBEC with prior RV-A16 exposure. (D) Suppression of seasonal IVA with prior RV-1B infection in HBEC. Error bars showing the SEM of means and asterisks indicating significance of $p < 0.05^*$, $p < 0.01^{**}$ and $p < 0.001^{***}$ compared with sham treatment as examined by one-sample t-test.